- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
India dismisses suits against drug regulators, whistleblower says
Mumbai: India's Supreme Court has refused to hear two lawsuits filed by one of the country's well-known whistleblowers which accused drugs and health regulators of failing to enforce safety standards, the whistleblower and his lawyer said on Friday.
Dinesh Thakur, who exposed dangerous practices in India's drugs industry in 2013, filed the public interest litigations in January, one of which alleges current drugs laws are "unconstitutional".
The suits sought a series of reforms, including harsher prosecution for manufacturers found to be selling substandard medicines or obtaining marketing approvals illegally.
Thakur, on his official Twitter account, said the Supreme Court refused to hear the cases on Friday and that he was "disappointed". He declined to comment on reasons for the refusal when contacted by Reuters, saying he had not yet received a court order.
Representatives at the Supreme Court, and the offices of the Central Drugs Standard Control Organisation and health ministry did not respond to requests for comment.
Thakur's lawyer and senior advocate at the Supreme Court, Raju Ramachandran, confirmed the court had refused to hear the cases. He declined to make any further comment.
"Unfortunately, the Supreme Court declined to admit either of the petitions but has given us liberty to approach any other appropriate forum for remedy," Thakur wrote on his blog.
He declined to comment on possible options when contacted by Reuters.
Dinesh Thakur, who exposed dangerous practices in India's drugs industry in 2013, filed the public interest litigations in January, one of which alleges current drugs laws are "unconstitutional".
The suits sought a series of reforms, including harsher prosecution for manufacturers found to be selling substandard medicines or obtaining marketing approvals illegally.
Thakur, on his official Twitter account, said the Supreme Court refused to hear the cases on Friday and that he was "disappointed". He declined to comment on reasons for the refusal when contacted by Reuters, saying he had not yet received a court order.
Representatives at the Supreme Court, and the offices of the Central Drugs Standard Control Organisation and health ministry did not respond to requests for comment.
Thakur's lawyer and senior advocate at the Supreme Court, Raju Ramachandran, confirmed the court had refused to hear the cases. He declined to make any further comment.
"Unfortunately, the Supreme Court declined to admit either of the petitions but has given us liberty to approach any other appropriate forum for remedy," Thakur wrote on his blog.
He declined to comment on possible options when contacted by Reuters.
Next Story